Vivo Bio Tech Ltd Financials
Company Logo

Vivo Bio Tech Ltd Financial Statement

Vivo Bio Tech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue12.44
Operating Expense7.15
Net Profit1.19
Net Profit Margin9.57
Earning Per Share0.78
EBIDTA5.61
Effective Tax Rate9.26

Vivo Bio Tech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual44.88
Operating Expenses Annual23.80
Operating Profit Annual21.12
Interest Annual7.78
Depreciation9.29
Net Profit Annual2.52
Tax Annual1.53

Vivo Bio Tech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.99
Cash Flow from Operations15.83
Cash Flow from Investing-7.95
Cash Flow from Financing-7.56
Cash Flow at the End1.32

Vivo Bio Tech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)47.46
PBIT Margin (%)26.76
PBT Margin (%)23.40
Net PROFIT Margin (%)5.61
Return On Networth / Equity (%)4.74
Return On Networth /Employed (%)10.06
Return On Assets (%)2.13
Total Debt / Equity (X)1.23
Asset Turnover Ratio (%)0.38

Vivo Bio Tech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual77.01
Total Current Assets Annual48.22
Non Current Assets Annual86.58
Total Shareholders Funds Annual54.40
Total Assets Annual134.80

Vivo Bio Tech Ltd Earning Calls

EPS (INR)

Expected

0.62

Reported

0.69

Surprise

11.29%

Dec 2024

EPS beaten by 11.29%

Sep 2024

EPS beaten by 7.84%

Jun 2024

EPS beaten by 0.00%

FAQS on Vivo Bio Tech Ltd Financials

As of Jun 1, 2025, Vivo Bio Tech Ltd has a market capitalization of 57.30 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Vivo Bio Tech Ltd is not with a debt-to-equity ratio of 0.66.

In FY 2024 , Vivo Bio Tech Ltd recorded a total revenue of approximately 46.67 Cr marking a significant milestone in the company's financial performance.

Vivo Bio Tech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and -0.1% annually, respectively..

Vivo Bio Tech Ltd's current PE ratio is 7.57.

Vivo Bio Tech Ltd's ROCE averaged 11.0% from the FY ending March 2023 to 2025, with a median of 10.9%. It peaked at 12.8% in March 2025, reflecting strong capital efficiency over the period..

Vivo Bio Tech Ltd's latest EBIT is Rs. 16.58 Cr, surpassing the average EBIT of Rs. 13.56 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions